NPR1 詳細
Molecule Name
Natriuretic peptide receptor 1
分子の別称
Atrial natriuretic peptide receptor 1,NPR1,NPRA,GC-A,ANPRA,NPR-A
Drug Development Progress
治験薬の数7
市販薬剤の数4
研究＆開発段階Approved
ターゲットの別称
EC:4.6.1.2，Atrionatriuretic Peptide Receptor A，Natriuretic Peptide Receptor A，ANPRA，Atrial Natriuretic Peptide Receptor 1，Natriuretic Peptide A Type Receptor，Testicular Tissue Protein Li 20，EC 4.6.1.2，GUCY2A，GUC2A，ANPa，NPRA，GC-A，NPR-A，NPR1，Guanylate cyclase A，ANP-A，Natriuretic Peptide Receptor 1，Atrial Natriuretic Peptide Receptor Type A，ANPR-A，Natriuretic Peptide Receptor A/Guanylate Cyclase A (Atrionatriuretic Peptide Receptor A)
バックグランド
Receptor for the atrial natriuretic peptide NPPA/ANP and the brain natriuretic peptide NPPB/BNP which are potent vasoactive hormones playing a key role in cardiovascular homeostasis. Has guanylate cyclase activity upon binding of the ligand.
NPR1 製品リスト
You Have Viewed 0 Of 0 Results
治験薬に関する情報
| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| Recombinant human brain natriuretic peptide(Shijiazhuang wotai) | Phase 3 Clinical | Shijiazhuang wotai Biotechnology Co Ltd | Acutely decompensated congestive heart failure; Heart Failure | 詳細 | |
| Recombinant human brain natriuretic peptide (Shanghai Jiao Tong University) | Phase 3 Clinical | Shanghai Jiaotong University | Heart Defects, Congenital; Tetralogy of Fallot | 詳細 | |
| Nesiritide | BNP-32 (human); JNS-004; hBNP; SC-70400 | Phase 2 Clinical | Johnson & Johnson | Acutely decompensated congestive heart failure; Cardiomyopathies; Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus; Dyspnea; Heart Failure; Heart Failure, Systolic; Hyperemia; Hyperinsulinism; Hypertension; Myocardial Ischemia; Obesity; Renal Insufficiency; Sleep Disorders, Circadian Rhythm | 詳細 |
| Baloncibart | REGN-7544; REGN7544 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Hypotension; Postural Orthostatic Tachycardia Syndrome | 詳細 |
| XXB-750 | XXB-750 | Phase 2 Clinical | Novartis Pharma Ag | Heart Failure; Heart Failure, Systolic; Hypertension | 詳細 |
| GNP | Phase 2 Clinical | Guangzhou Leien Kangya Biomedical Technology Co Ltd | Acutely decompensated congestive heart failure; Heart Failure | 詳細 | |
| REGN-5381 | REGN-5381 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Heart Failure; Hypertension | 詳細 |
市販薬剤に関する情報
| 英語名 | 研究コード | 研究開発ステージ | 会社 | オリジナル製品名 | 最初に承認をした国 | 最初の適応症 | 最初に承認を受けた会社 | 承認された日付 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|---|---|---|---|---|
| Recombinant human brain natriuretic peptide (Tibet Rhodiola) | Approved | Tibet Rhodiola Pharmaceutical Holding Company | 新活素 | Mainland China | Heart Failure | Chengdu Rhodiola Bio-Pharmaceutical Co Ltd | 2005-04-11 | Acutely decompensated congestive heart failure; Heart Failure | 詳細 | |
| Sodium Nitroprusside | SNP | Approved | F. Hoffmann-La Roche Ltd | Nipride, Nitriate, Nitropress | Mainland China | Heart Failure; Hypertension | China Resources Double-Crane Pharmaceutical Co Ltd | 1974-05-10 | Healthy Aging; Heart Failure; Hypertension; Hypotension; Myocardial Infarction; Pulmonary Edema; Schizophrenia | 詳細 |
| Recombinant human brain natriuretic peptide (Suzhou Landing Bioteh) | Approved | Suzhou RxD Biopharmaceutical Co Ltd | Mainland China | Heart Failure | Suzhou RxD Biopharmaceutical Co Ltd | 2025-04-30 | Heart Failure | 詳細 | ||
| Carperitide | SUN-Y4936r; alpha-hANP; ANF (99-126); SUN-4936r; ANP (99-126); CDD (99-126); SUN-4936; SUN-4936h | Approved | Daiichi Sankyo Co Ltd | HANP | Japan | Heart Failure | Daiichi Sankyo Co Ltd | 1995-01-20 | Cardiomyopathies; Heart Failure; Respiratory Distress Syndrome, Adult | 詳細 |